These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum. Seiler MP; Markstein R Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231 [TBL] [Abstract][Full Text] [Related]
3. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors. Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114 [TBL] [Abstract][Full Text] [Related]
4. Aminopyrimidines with high affinity for both serotonin and dopamine receptors. Wustrow D; Belliotti T; Glase S; Kesten SR; Johnson D; Colbry N; Rubin R; Blackburn A; Akunne H; Corbin A; Davis MD; Georgic L; Whetzel S; Zoski K; Heffner T; Pugsley T; Wise L J Med Chem; 1998 Feb; 41(5):760-71. PubMed ID: 9513604 [TBL] [Abstract][Full Text] [Related]
6. Dopaminergic 2-aminotetralins: affinities for dopamine D2-receptors, molecular structures, and conformational preferences. Johansson AM; Karlén A; Grol CJ; Sundell S; Kenne L; Hacksell U Mol Pharmacol; 1986 Sep; 30(3):258-69. PubMed ID: 2943981 [TBL] [Abstract][Full Text] [Related]
7. Dopamine D2 receptor binding sites for agonists. A tetrahedral model. Seeman P; Watanabe M; Grigoriadis D; Tedesco JL; George SR; Svensson U; Nilsson JL; Neumeyer JL Mol Pharmacol; 1985 Nov; 28(5):391-9. PubMed ID: 2932631 [TBL] [Abstract][Full Text] [Related]
8. High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains. Robinson SW; Jarvie KR; Caron MG Mol Pharmacol; 1994 Aug; 46(2):352-6. PubMed ID: 7915820 [TBL] [Abstract][Full Text] [Related]
9. Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens. Rouillon C; Degoulet M; Chevallier K; Abraini JH; David HN Brain Res; 2008 Mar; 1198():44-54. PubMed ID: 18261716 [TBL] [Abstract][Full Text] [Related]
10. Topography and conformational preferences of 6,7,8,9-tetrahydro-1-hydroxy-N,N-dipropyl-5H-benzocyclohepten-6- ylamin e. A rationale for the dopaminergic inactivity. Karlén A; Helander A; Kenne L; Hacksell U J Med Chem; 1989 Apr; 32(4):765-74. PubMed ID: 2522990 [TBL] [Abstract][Full Text] [Related]
12. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor model. Seiler MP; Markstein R; Walkinshaw MD; Boelsterli JJ Mol Pharmacol; 1989 May; 35(5):643-51. PubMed ID: 2566903 [TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptor model explains binding affinity of neuroleptics: piquindone and its structure activity relationships. Teeter MM; Durand CJ Drug Des Discov; 1996 Apr; 13(3-4):49-62. PubMed ID: 8874043 [No Abstract] [Full Text] [Related]
14. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. Hess EJ; Albers LJ; Le H; Creese I J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223 [TBL] [Abstract][Full Text] [Related]
15. New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. Mewshaw RE; Kavanagh J; Stack G; Marquis KL; Shi X; Kagan MZ; Webb MB; Katz AH; Park A; Kang YH; Abou-Gharbia M; Scerni R; Wasik T; Cortes-Burgos L; Spangler T; Brennan JA; Piesla M; Mazandarani H; Cockett MI; Ochalski R; Coupet J; Andree TH J Med Chem; 1997 Dec; 40(26):4235-56. PubMed ID: 9435894 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Enjalbert A; Bockaert J Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological evaluation of thiazole and isothiazole derived apomorphines. Sipos A; Mueller FK; Lehmann J; Berényi S; Antus S Arch Pharm (Weinheim); 2009 Oct; 342(10):557-68. PubMed ID: 19714675 [TBL] [Abstract][Full Text] [Related]
19. The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. Kilpatrick GJ; el Tayar N; Van de Waterbeemd H; Jenner P; Testa B; Marsden CD Mol Pharmacol; 1986 Sep; 30(3):226-34. PubMed ID: 2943980 [TBL] [Abstract][Full Text] [Related]
20. Dopamine D4 receptors elevated in schizophrenia. Seeman P; Guan HC; Van Tol HH Nature; 1993 Sep; 365(6445):441-5. PubMed ID: 8413587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]